Literature DB >> 10360641

Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.

D Seth1, K Shaw, J Jazayeri, P J Leedman.   

Abstract

The epidermal growth factor receptor (EGFR) plays an important role in the development and progression of prostate cancer and its overexpression is associated with decreased survival. With progression, prostate cancer cells switch from epidermal growth factor (EGF) to transforming growth factor alpha (TGF-alpha) synthesis, which contributes to autocrine growth and unrestrained proliferation. To define the molecular mechanisms involved in the regulation of EGFR expression by EGF and TGF-alpha we studied three human prostate cancer cell lines, androgen-responsive (LNCaP) and -unresponsive (DU145 and PC3). Here we show that TGF-alpha stabilized EGFR mRNA two- to threefold in all three cell lines, whilst EGF stabilized EGFR mRNA approximately twofold in LNCaP and DU145 cells, but not in PC3 cells. Both ligands increased EGFR transcription in LNCaP and DU145 cells, with less effect in PC3 cells. In all three cell lines EGF reduced total EGFR protein levels more than TGF-alpha, but this was associated with a greater increase in de novo protein synthesis with EGF compared to TGF-alpha. Only EGF, however, shortened EGFR protein stability (half-life decreased from 5 h to 120 min), resulting in rapid disappearance of newly synthesized EGFR protein. Both ligands increased total LNCaP and DU145 cell numbers. These studies demonstrate that the EGF- and TGF-alpha-induced upregulation of EGFR mRNA and protein in human prostate cancer cell lines is complex and occurs at multiple, transcriptional and post-transcriptional levels. Taken together, these data provide novel insight into the molecular mechanisms by which TGF-alpha would preferentially maintain an autocrine loop in human prostate cancer cells. Furthermore, this work suggests that in human prostate cancer cells ligand-specific differential intracellular trafficking of the EGFR plays a major role in regulating its expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360641      PMCID: PMC2362295          DOI: 10.1038/sj.bjc.6690407

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  53 in total

1.  Thyroid hormone decreases the expression of epidermal growth factor receptor.

Authors:  P Kesavan; S Mukhopadhayay; S Murphy; M Rengaraju; M A Lazar; M Das
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

2.  Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha.

Authors:  D R Hofer; E R Sherwood; W D Bromberg; J Mendelsohn; C Lee; J M Kozlowski
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

3.  The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor.

Authors:  H S Wiley; J J Herbst; B J Walsh; D A Lauffenburger; M G Rosenfeld; G N Gill
Journal:  J Biol Chem       Date:  1991-06-15       Impact factor: 5.157

4.  Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines.

Authors:  G L Morris; J G Dodd
Journal:  J Urol       Date:  1990-06       Impact factor: 7.450

5.  Transcriptional regulation of proto-oncogene expression by epidermal growth factor, transforming growth factor beta 1, and triiodothyronine in MDA-468 cells.

Authors:  J A Fernandez-Pol; P D Hamilton; D J Klos
Journal:  J Biol Chem       Date:  1989-03-05       Impact factor: 5.157

6.  Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells.

Authors:  B W Ennis; E M Valverius; S E Bates; M E Lippman; F Bellot; R Kris; J Schlessinger; H Masui; A Goldenberg; J Mendelsohn
Journal:  Mol Endocrinol       Date:  1989-11

7.  Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line.

Authors:  J M Connolly; D P Rose
Journal:  Prostate       Date:  1990       Impact factor: 4.104

Review 8.  Peptide growth factors in the prostate as mediators of stromal epithelial interaction.

Authors:  R L Byrne; H Leung; D E Neal
Journal:  Br J Urol       Date:  1996-05

9.  Role of transforming growth factor-alpha in human prostate cancer cell growth.

Authors:  G Wilding; E Valverius; C Knabbe; E P Gelmann
Journal:  Prostate       Date:  1989       Impact factor: 4.104

10.  Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumour.

Authors:  S Q Maddy; G D Chisholm; A Busuttil; F K Habib
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

View more
  19 in total

1.  Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells.

Authors:  Sumit Bhattacharyya; Leo Feferman; Xiaorui Han; Yilan Ouyang; Fuming Zhang; Robert J Linhardt; Joanne K Tobacman
Journal:  J Biol Chem       Date:  2018-05-24       Impact factor: 5.157

2.  Identification of a novel AU-Rich element in the 3' untranslated region of epidermal growth factor receptor mRNA that is the target for regulated RNA-binding proteins.

Authors:  L A Balmer; D J Beveridge; J A Jazayeri; A M Thomson; C E Walker; P J Leedman
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Bax expression remains unchanged following antisense treatment directed against BCL-2.

Authors:  Marvin Rubenstein; Courtney M P Hollowell; Patrick Guinan
Journal:  Med Oncol       Date:  2010-04-27       Impact factor: 3.064

4.  Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.

Authors:  Cheryl A London; Jaime Acquaviva; Donald L Smith; Manuel Sequeira; Luisa Shin Ogawa; Heather L Gardner; Louis Feo Bernabe; Misty D Bear; Sandra A Bechtel; David A Proia
Journal:  Clin Cancer Res       Date:  2018-08-31       Impact factor: 12.531

5.  Sox2 targets cyclinE, p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis.

Authors:  F Lin; P Lin; D Zhao; Y Chen; L Xiao; W Qin; D Li; H Chen; B Zhao; H Zou; X Zheng; X Yu
Journal:  Cell Prolif       Date:  2012-04-02       Impact factor: 6.831

6.  EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling.

Authors:  Alyse M DeHaan; Natalie M Wolters; Evan T Keller; Kathleen M Woods Ignatoski
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

7.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Authors:  Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

8.  Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model.

Authors:  Takamitsu Sasaki; Toru Nakamura; Robert B Rebhun; Hua Cheng; Katherine Stemke Hale; Rachel Z Tsan; Isaiah J Fidler; Robert R Langley
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

9.  Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.

Authors:  Jeannine Garnett; Vaibhav Chumbalkar; Brian Vaillant; Anupama E Gururaj; Kristen S Hill; Khatri Latha; Jun Yao; Waldemar Priebe; Howard Colman; Lisa A Elferink; Oliver Bogler
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

10.  Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3.

Authors:  Mengqian Chen; Ya-Yuan Fu; Chen-Yong Lin; Li-Mei Chen; Karl X Chai
Journal:  Biochim Biophys Acta       Date:  2007-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.